24 HR dapagliflozin 5 MG / metformin hydrochloride 1000 MG Extended Release Oral Tablet
- RxCUI
- 1593070
- RxNorm name
- 24 HR dapagliflozin 5 MG / metformin hydrochloride 1000 MG Extended Release Oral Tablet
- Display name
- Dapagliflozin/metFORMIN XR (Oral Pill)
- Full name
- 24 HR dapagliflozin 5 MG / metformin hydrochloride 1000 MG Extended Release Oral Tablet
- Term type
- SCD
- Status
- Active
- Strength
- 5-1,000 mg
- Dose form
- 24 HR XR Tab
- Route
- Oral Pill
- Updated
- 2026-10-15 14:49:19
RxNorm Status History#
- Status
- Active
- Source
- RXNORM
- Current
- YES
- Release start
- 122014
- Active start
- 122014
- Multiple ingredient
- YES
- Branded
- NO
Ingredients And Strength#
| Ingredient | Strength | Base | Basis of strength |
|---|---|---|---|
| dapagliflozin propanediol | 5 MG / 1 EACH | dapagliflozin | dapagliflozin |
| metformin hydrochloride | 1000 MG / 1 EACH | metformin | metformin hydrochloride |
Dose Form Concepts#
| Dose form | RxCUI |
|---|---|
| Extended Release Oral Tablet | 316945 |
Derived Ingredient Concepts#
| Ingredient | RxCUI |
|---|---|
| dapagliflozin | 1488564 |
| metformin | 6809 |
Source Vocabulary Codes#
| Code type | Values | Count | Category |
|---|---|---|---|
| PRESCRIBABLE | Y | 1 | ATTRIBUTES |
| RXNAV_STR | 24 HR dapagliflozin 5 MG / metFORMIN hydrochloride 1000 MG Extended Release Oral Tablet | 1 | NAMES |
| RxNorm Name | 24 HR dapagliflozin 5 MG / metformin hydrochloride 1000 MG Extended Release Oral Tablet | 1 | NAMES |
| RxNorm Synonym | dapagliflozin (as dapagliflozin propanediol) 5 MG / metformin hydrochloride 1000 MG 24 HR Extended Release Oral Tablet | 1 | NAMES |
| TTY | SCD | 1 | ATTRIBUTES |
| SPL_SET_ID | 8 linked values | 8 | CODES |
| RxCUI | 1593070 | 1 | CODES |
| MMSL_CODE | 2 | CODES |
FDA NDC Products And Packages#
| Package NDC | Product NDC | Name | Labeler | Application |
|---|---|---|---|---|
| 33342-408-06 | 33342-408 | Dapagliflozin and Metformin Hydrochloride Dapagliflozin and Metformin Hydrochloride | Macleods Pharmaceuticals Limited | ANDA211559 |
| 33342-408-07 | 33342-408 | Dapagliflozin and Metformin Hydrochloride Dapagliflozin and Metformin Hydrochloride | Macleods Pharmaceuticals Limited | ANDA211559 |
| 33342-408-09 | 33342-408 | Dapagliflozin and Metformin Hydrochloride Dapagliflozin and Metformin Hydrochloride | Macleods Pharmaceuticals Limited | ANDA211559 |
| 33342-408-10 | 33342-408 | Dapagliflozin and Metformin Hydrochloride Dapagliflozin and Metformin Hydrochloride | Macleods Pharmaceuticals Limited | ANDA211559 |
| 33342-408-15 | 33342-408 | Dapagliflozin and Metformin Hydrochloride Dapagliflozin and Metformin Hydrochloride | Macleods Pharmaceuticals Limited | ANDA211559 |
| 59651-155-04 | 59651-155 | Dapagliflozin and Metformin hydrochloride Dapagliflozin and Metformin hydrochloride | Aurobindo Pharma Limited | ANDA211489 |
| 59651-155-30 | 59651-155 | Dapagliflozin and Metformin hydrochloride Dapagliflozin and Metformin hydrochloride | Aurobindo Pharma Limited | ANDA211489 |
| 59651-155-60 | 59651-155 | Dapagliflozin and Metformin hydrochloride Dapagliflozin and Metformin hydrochloride | Aurobindo Pharma Limited | ANDA211489 |
| 63304-026-30 | 63304-026 | Dapagliflozin and Metformin Hydrochloride Dapagliflozin and Metformin Hydrochloride | Sun Pharmaceutical Industries, Inc. | ANDA211491 |
| 63304-026-54 | 63304-026 | Dapagliflozin and Metformin Hydrochloride Dapagliflozin and Metformin Hydrochloride | Sun Pharmaceutical Industries, Inc. | ANDA211491 |
| 63304-026-62 | 63304-026 | Dapagliflozin and Metformin Hydrochloride Dapagliflozin and Metformin Hydrochloride | Sun Pharmaceutical Industries, Inc. | ANDA211491 |
| 66993-361-60 | 66993-361 | dapagliflozin and metformin hydrochloride dapagliflozin and metformin hydrochloride | Prasco Laboratories | NDA205649 |
| 67877-620-30 | 67877-620 | dapagliflozin and metformin hydrochloride dapagliflozin and metformin hydrochloride | Ascend Laboratories, LLC | ANDA211563 |
| 67877-620-60 | 67877-620 | dapagliflozin and metformin hydrochloride dapagliflozin and metformin hydrochloride | Ascend Laboratories, LLC | ANDA211563 |
| 67877-620-90 | 67877-620 | dapagliflozin and metformin hydrochloride dapagliflozin and metformin hydrochloride | Ascend Laboratories, LLC | ANDA211563 |
| 70748-102-07 | 70748-102 | DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | Lupin Pharmaceuticals, Inc. | ANDA211579 |
| 72205-435-01 | 72205-435 | DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | Novadoz Pharmaceuticals LLC | ANDA211479 |
| 72205-435-02 | 72205-435 | DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | Novadoz Pharmaceuticals LLC | ANDA211479 |
| 72205-435-03 | 72205-435 | DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | Novadoz Pharmaceuticals LLC | ANDA211479 |
| 84677-020-60 | 84677-020 | Dapagliflozin and Metformin Hydrochloride Dapagliflozin and Metformin Hydrochloride | Golden State Medical Supply, Inc. | ANDA211491 |
Drugs@FDA Applications#
| Application | NDC | Name | Marketing category | Labeler |
|---|---|---|---|---|
| ANDA211559 | 33342-408 | Dapagliflozin and Metformin Hydrochloride Dapagliflozin and Metformin Hydrochloride | ANDA | Macleods Pharmaceuticals Limited |
| ANDA211489 | 59651-155 | Dapagliflozin and Metformin hydrochloride Dapagliflozin and Metformin hydrochloride | ANDA | Aurobindo Pharma Limited |
| ANDA211491 | 63304-026 | Dapagliflozin and Metformin Hydrochloride Dapagliflozin and Metformin Hydrochloride | ANDA | Sun Pharmaceutical Industries, Inc. |
| NDA205649 | 66993-361 | dapagliflozin and metformin hydrochloride dapagliflozin and metformin hydrochloride | NDA AUTHORIZED GENERIC | Prasco Laboratories |
| ANDA211563 | 67877-620 | dapagliflozin and metformin hydrochloride dapagliflozin and metformin hydrochloride | ANDA | Ascend Laboratories, LLC |
| ANDA211579 | 70748-102 | DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | ANDA | Lupin Pharmaceuticals, Inc. |
| ANDA211479 | 72205-435 | DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | ANDA | Novadoz Pharmaceuticals LLC |
UNII Substances#
No records found.
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| XIGDUO XR | DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | AstraZeneca Pharmaceuticals LP | ac8a0f7b-9f69-4495-abbc-3a47cd75a859 | 2026-08-11 | Boxed warning, Warnings, Adverse reactions | 1593070 |
| Dapagliflozin and Metformin Hydrochloride | DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | Golden State Medical Supply, Inc. | 54027b70-53e7-3710-e063-6394a90aa04c | 2026-06-11 | Boxed warning, Warnings, Adverse reactions | 84677-020-60 84677-020 84677002060 1593070 |
| DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | Novadoz Pharmaceuticals LLC | 4f890458-be94-4baf-b606-83a097e1e23e | 2026-04-09 | Boxed warning, Warnings, Adverse reactions | 72205-435-03 72205-435-02 72205-435-01 72205-435 72205043502 72205043503 72205043501 1593070 |
| dapagliflozin and metformin hydrochloride | DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | Ascend Laboratories, LLC | eadcc3ef-f5c2-4a56-a6aa-12909844144e | 2026-03-18 | Boxed warning, Warnings, Adverse reactions | 67877-620-60 67877-620-30 67877-620-90 67877-620 67877062060 67877062030 67877062090 1593070 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
DailyMed RxNorm Mappings#
| Set ID | RxNorm mappings | Terms | SPL version | Label | Effective |
|---|---|---|---|---|---|
| ac8a0f7b-9f69-4495-abbc-3a47cd75a859 | dapagliflozin 5 MG / metFORMIN HCl 1000 MG 24HR Extended Release Oral Tablet [PSN] · 24 HR dapagliflozin 5 MG / metformin hydrochloride 1000 MG Extended Release Oral Tablet [SCD] · dapagliflozin (as dapagliflozin propanediol) 5 MG / metformin hydrochloride 1000 MG 24 HR Extended Release Oral Tablet [SY] | 3 | 38 | These highlights do not include all the information needed to use XIGDUO XR safely and effectively. See full prescribing information for XIGDUO XR. XIGDUO ® XR (dapagliflozin and metformin hydrochloride extended-release) tablets, for oral use Initial U.S. Approval: 2014 | 20241220 |
| e6957674-86c1-4536-8e23-54ad7f2cacc4 | dapagliflozin 5 MG / metFORMIN HCl 1000 MG 24HR Extended Release Oral Tablet [PSN] · 24 HR dapagliflozin 5 MG / metformin hydrochloride 1000 MG Extended Release Oral Tablet [SCD] · dapagliflozin (as dapagliflozin propanediol) 5 MG / metformin hydrochloride 1000 MG 24 HR Extended Release Oral Tablet [SY] | 3 | 15 | These highlights do not include all the information needed to use DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS. DAPAGLIFLOZIN and METFORMIN HYDROCHLORIDE extended-release tablets, for oral use Initial U.S. Approval: 2014 | 20260421 |
| eadcc3ef-f5c2-4a56-a6aa-12909844144e | dapagliflozin 5 MG / metFORMIN HCl 1000 MG 24HR Extended Release Oral Tablet [PSN] · 24 HR dapagliflozin 5 MG / metformin hydrochloride 1000 MG Extended Release Oral Tablet [SCD] · dapagliflozin (as dapagliflozin propanediol) 5 MG / metformin hydrochloride 1000 MG 24 HR Extended Release Oral Tablet [SY] | 3 | 14 | These highlights do not include all the information needed to use DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS. DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE extended-release tablets, for oral use Initial U.S. Approval: 2014 | 20260318 |
| eaf135b6-e378-4f62-a1e7-db45e23668c7 | dapagliflozin 5 MG / metFORMIN HCl 1000 MG 24HR Extended Release Oral Tablet [PSN] · 24 HR dapagliflozin 5 MG / metformin hydrochloride 1000 MG Extended Release Oral Tablet [SCD] · dapagliflozin (as dapagliflozin propanediol) 5 MG / metformin hydrochloride 1000 MG 24 HR Extended Release Oral Tablet [SY] | 3 | 7 | These highlights do not include all the information needed to use DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE EXTENDED‑RELEASE TABLETS safely and effectively. See full prescribing information for DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE EXTENDED‑RELEASE TABLETS. DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE EXTENDED‑RELEASE tablets, for oral use Initial U.S. Approval: 2014 | 20241220 |
| bddc2d47-8d3d-4c2f-8e5c-7a1a0782219a | dapagliflozin 5 MG / metFORMIN HCl 1000 MG 24HR Extended Release Oral Tablet [PSN] · 24 HR dapagliflozin 5 MG / metformin hydrochloride 1000 MG Extended Release Oral Tablet [SCD] · dapagliflozin (as dapagliflozin propanediol) 5 MG / metformin hydrochloride 1000 MG 24 HR Extended Release Oral Tablet [SY] | 3 | 2 | These highlights do not include all the information needed to use DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE EXTENDED RELEASE TABLETS safely and effectively. See full prescribing information for DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE EXTENDED RELEASE TABLETS. DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE extended release tablets, for oral use Initial U.S. Approval: 2014 | 20260331 |
| 4f890458-be94-4baf-b606-83a097e1e23e | dapagliflozin 5 MG / metFORMIN HCl 1000 MG 24HR Extended Release Oral Tablet [PSN] · 24 HR dapagliflozin 5 MG / metformin hydrochloride 1000 MG Extended Release Oral Tablet [SCD] · dapagliflozin (as dapagliflozin propanediol) 5 MG / metformin hydrochloride 1000 MG 24 HR Extended Release Oral Tablet [SY] | 3 | 1 | These highlights do not include all the information needed to use DAPAGLIFLOZIN AND METFORMIN HCL EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for DAPAGLIFLOZIN AND METFORMIN HCL EXTENDED-RELEASE TABLETS. DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE extended-release tablets, for oral use Initial U.S. Approval: 2014 | 20260409 |
| 513bdf9f-774c-4f7f-935a-54d3885e80a4 | dapagliflozin 5 MG / metFORMIN HCl 1000 MG 24HR Extended Release Oral Tablet [PSN] · 24 HR dapagliflozin 5 MG / metformin hydrochloride 1000 MG Extended Release Oral Tablet [SCD] · dapagliflozin (as dapagliflozin propanediol) 5 MG / metformin hydrochloride 1000 MG 24 HR Extended Release Oral Tablet [SY] | 3 | 1 | These highlights do not include all the information needed to use DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS. DAPAGLIFLOZIN and METFORMIN HYDROCHLORIDE extended-release tablets, for oral use Initial U.S. Approval: 2014 | 20260407 |
| 7d575ca8-9c1f-469d-a341-34daf2f036dd | dapagliflozin 5 MG / metFORMIN HCl 1000 MG 24HR Extended Release Oral Tablet [PSN] · 24 HR dapagliflozin 5 MG / metformin hydrochloride 1000 MG Extended Release Oral Tablet [SCD] · dapagliflozin (as dapagliflozin propanediol) 5 MG / metformin hydrochloride 1000 MG 24 HR Extended Release Oral Tablet [SY] | 3 | 1 | These highlights do not include all the information needed to use DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE extended-release tablets, for oral use Initial U.S. Approval: 2014 | 20260331 |
Recently Linked DailyMed Labels#
| Set ID | Title | Manufacturer | Effective |
|---|---|---|---|
| bddc2d47-8d3d-4c2f-8e5c-7a1a0782219a | These highlights do not include all the information needed to use DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS. DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE extended-release tablets, for oral use Initial U.S. Approval: 2014 | Sun Pharmaceutical Industries, Inc. | Ohm Laboratories Inc. | 20260917 |
| 7d575ca8-9c1f-469d-a341-34daf2f036dd | These highlights do not include all the information needed to use DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE extended-release tablets, for oral use Initial U.S. Approval: 2014 | Macleods Pharmaceuticals Limited | 20260916 |
| e6957674-86c1-4536-8e23-54ad7f2cacc4 | These highlights do not include all the information needed to use DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS. DAPAGLIFLOZIN and METFORMIN HYDROCHLORIDE extended-release tablets, for oral use Initial U.S. Approval: 2014 | Lupin Pharmaceuticals, Inc. | LUPIN LIMITED | 20260908 |
| 513bdf9f-774c-4f7f-935a-54d3885e80a4 | These highlights do not include all the information needed to use DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS. DAPAGLIFLOZIN and METFORMIN HYDROCHLORIDE extended-release tablets, for oral use Initial U.S. Approval: 2014 | Aurobindo Pharma Limited | APL HEALTHCARE LIMITED | 20260902 |
| eaf135b6-e378-4f62-a1e7-db45e23668c7 | These highlights do not include all the information needed to use DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE EXTENDED‑RELEASE TABLETS safely and effectively. See full prescribing information for DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE EXTENDED‑RELEASE TABLETS. DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE EXTENDED‑RELEASE tablets, for oral use Initial U.S. Approval: 2014 | Prasco Laboratories | AstraZeneca PLC | AstraZeneca Pharmaceuticals LP | 20260801 |
| 54027b70-53e7-3710-e063-6394a90aa04c | DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE EXTENDED RELEASE TABLETS. These highlights do not include all the information needed to use DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE EXTENDED RELEASE TABLETS safely and effectively. See full prescribing information for DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE EXTENDED RELEASE TABLETS. DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE extended release tablets, for oral use Initial U.S. Approval: 2014 | Golden State Medical Supply, Inc. | 20260611 |
| e6957674-86c1-4536-8e23-54ad7f2cacc4 | These highlights do not include all the information needed to use DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS. DAPAGLIFLOZIN and METFORMIN HYDROCHLORIDE extended-release tablets, for oral use Initial U.S. Approval: 2014 | Lupin Pharmaceuticals, Inc. | LUPIN LIMITED | 20260421 |
| 4f890458-be94-4baf-b606-83a097e1e23e | These highlights do not include all the information needed to use DAPAGLIFLOZIN AND METFORMIN HCL EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for DAPAGLIFLOZIN AND METFORMIN HCL EXTENDED-RELEASE TABLETS. DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE extended-release tablets, for oral use Initial U.S. Approval: 2014 | Novadoz Pharmaceuticals LLC | MSN LABORATORIES PRIVATE LIMITED | 20260409 |
| 513bdf9f-774c-4f7f-935a-54d3885e80a4 | These highlights do not include all the information needed to use DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS. DAPAGLIFLOZIN and METFORMIN HYDROCHLORIDE extended-release tablets, for oral use Initial U.S. Approval: 2014 | Aurobindo Pharma Limited | APL HEALTHCARE LIMITED | 20260407 |
| bddc2d47-8d3d-4c2f-8e5c-7a1a0782219a | These highlights do not include all the information needed to use DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE EXTENDED RELEASE TABLETS safely and effectively. See full prescribing information for DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE EXTENDED RELEASE TABLETS. DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE extended release tablets, for oral use Initial U.S. Approval: 2014 | Sun Pharmaceutical Industries, Inc. | 20260331 |
| 7d575ca8-9c1f-469d-a341-34daf2f036dd | These highlights do not include all the information needed to use DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE extended-release tablets, for oral use Initial U.S. Approval: 2014 | Macleods Pharmaceuticals Limited | 20260331 |
| eadcc3ef-f5c2-4a56-a6aa-12909844144e | These highlights do not include all the information needed to use DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS. DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE extended-release tablets, for oral use Initial U.S. Approval: 2014 | Ascend Laboratories, LLC | Alkem Laboratories Limited | 20260318 |
| eaf135b6-e378-4f62-a1e7-db45e23668c7 | These highlights do not include all the information needed to use DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE EXTENDED‑RELEASE TABLETS safely and effectively. See full prescribing information for DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE EXTENDED‑RELEASE TABLETS. DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE EXTENDED‑RELEASE tablets, for oral use Initial U.S. Approval: 2014 | Prasco Laboratories | AstraZeneca PLC | 20241220 |
Drug Classes#
| Source | Class ID | Class | Type | Relationship | Drug concept |
|---|---|---|---|---|---|
| ATC | A10BA | Biguanides | ATC1-4 | metformin | |
| ATC | A10BD | Combinations of oral blood glucose lowering drugs | ATC1-4 | dapagliflozin / metformin | |
| ATC | A10BK | Sodium-glucose co-transporter 2 (SGLT2) inhibitors | ATC1-4 | dapagliflozin | |
| FDASPL | D001645 | Biguanides | CHEM | has_chemical_structure | metformin |
| FDASPL | N0000175565 | Biguanide | EPC | has_epc | metformin |
| FDASPL | N0000187059 | Sodium-Glucose Cotransporter 2 Inhibitor | EPC | has_epc | dapagliflozin |
| FDASPL | N0000187058 | Sodium-Glucose Transporter 2 Inhibitors | MOA | has_moa | dapagliflozin |
| MEDRT | D001559 | Benzhydryl Compounds | CHEM | has_ingredient | dapagliflozin |
| MEDRT | D005960 | Glucosides | CHEM | has_ingredient | dapagliflozin |
| MEDRT | D008687 | Metformin | CHEM | has_ingredient | metformin |
| MEDRT | D008687 | Metformin | CHEM | has_ingredient | metformin hydrochloride |
| MEDRT | D000138 | Acidosis | DISEASE | ci_with | metformin hydrochloride |
| MEDRT | D000138 | Acidosis | DISEASE | ci_with | metformin |
| MEDRT | D003924 | Diabetes Mellitus, Type 2 | DISEASE | may_treat | metformin |
| MEDRT | D003924 | Diabetes Mellitus, Type 2 | DISEASE | may_treat | dapagliflozin |
| MEDRT | D003924 | Diabetes Mellitus, Type 2 | DISEASE | may_treat | metformin hydrochloride |
| MEDRT | D016883 | Diabetic Ketoacidosis | DISEASE | ci_with | metformin |
| MEDRT | D016883 | Diabetic Ketoacidosis | DISEASE | ci_with | metformin hydrochloride |
| MEDRT | D004342 | Drug Hypersensitivity | DISEASE | ci_with | metformin hydrochloride |
| MEDRT | D004342 | Drug Hypersensitivity | DISEASE | ci_with | metformin |
| MEDRT | D006333 | Heart Failure | DISEASE | may_treat | dapagliflozin |
| MEDRT | D008107 | Liver Diseases | DISEASE | ci_with | metformin hydrochloride |
| MEDRT | D008107 | Liver Diseases | DISEASE | ci_with | metformin |
| MEDRT | D051437 | Renal Insufficiency | DISEASE | ci_with | metformin hydrochloride |
| MEDRT | D051437 | Renal Insufficiency | DISEASE | ci_with | metformin |
| MEDRT | N0000000225 | Insulin Receptor Agonists | MOA | has_moa | metformin |
| MEDRT | N0000000225 | Insulin Receptor Agonists | MOA | has_moa | metformin hydrochloride |
| MEDRT | N0000187058 | Sodium-Glucose Transporter 2 Inhibitors | MOA | has_moa | dapagliflozin |
| MEDRT | N0000008646 | Decreased Gluconeogenesis | PE | has_pe | metformin hydrochloride |
| MEDRT | N0000008646 | Decreased Gluconeogenesis | PE | has_pe | metformin |
| MEDRT | N0000008650 | Decreased Glycogenesis | PE | has_pe | metformin |
| MEDRT | N0000008650 | Decreased Glycogenesis | PE | has_pe | metformin hydrochloride |
| MEDRT | N0000175650 | Decreased Sympathetic Activity | PE | has_pe | dapagliflozin |
| MEDRT | N0000009341 | Increased Glucose Transport into Cells | PE | has_pe | metformin hydrochloride |
| MEDRT | N0000009341 | Increased Glucose Transport into Cells | PE | has_pe | metformin |
| MEDRT | N0000009556 | Increased Renal Organic Ion Excretion | PE | has_pe | dapagliflozin |
| MEDRT | N0000009830 | Renal Ion Transport Alteration | PE | has_pe | dapagliflozin |
| MEDRT | N0000000042 | Renal Excretion | PK | has_pk | metformin |
| MEDRT | N0000000042 | Renal Excretion | PK | has_pk | metformin hydrochloride |
Properties#
| Category | Property | Value |
|---|---|---|
| ATTRIBUTES | AVAILABLE_STRENGTH | 5 MG / 1000 MG |
| ATTRIBUTES | GENERAL_CARDINALITY | MULTI |
| ATTRIBUTES | HUMAN_DRUG | US |
| ATTRIBUTES | QUANTITY | 24 HR |
| ATTRIBUTES | RXNAV_HUMAN_DRUG | US |
| ATTRIBUTES | SCHEDULE | 0 |
| CODES | ANDA | ANDA211479 |
| CODES | ANDA | ANDA211489 |
| CODES | ANDA | ANDA211491 |
| CODES | ANDA | ANDA211559 |
| CODES | ANDA | ANDA211563 |
| CODES | ANDA | ANDA211579 |
| CODES | VUID | 4033847 |
| NAMES | Prescribable Synonym | dapagliflozin 5 MG / metFORMIN HCl 1000 MG 24HR Extended Release Oral Tablet |
| NAMES | Tallman Synonym | 24 HR dapagliflozin 5 MG / metFORMIN hydrochloride 1000 MG Extended Release Oral Tablet |
| NAMES | Tallman Synonym | dapagliflozin (as dapagliflozin propanediol) 5 MG / metFORMIN hydrochloride 1000 MG 24 HR Extended Release Oral Tablet |
| SOURCES | Source | Gold Standard Alchemy |
| SOURCES | Source | Metathesaurus FDA Structured Product Labels |
| SOURCES | Source | Micromedex RED BOOK |
| SOURCES | Source | Multum MediSource Lexicon |
| SOURCES | Source | National Drug Data File Plus Source Vocabulary |
| SOURCES | Source | Veterans Health Administration National Drug File |